CN115461330A - FXIa抑制剂化合物杂质及其制备方法和用途 - Google Patents

FXIa抑制剂化合物杂质及其制备方法和用途 Download PDF

Info

Publication number
CN115461330A
CN115461330A CN202280003731.4A CN202280003731A CN115461330A CN 115461330 A CN115461330 A CN 115461330A CN 202280003731 A CN202280003731 A CN 202280003731A CN 115461330 A CN115461330 A CN 115461330A
Authority
CN
China
Prior art keywords
compound
impurity
inhibitor compound
fxia inhibitor
fxia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280003731.4A
Other languages
English (en)
Inventor
连小磊
许文杰
华怀杰
陈淑君
李亲泽
陈相孟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Salubris Pharmaceuticals Co Ltd
Original Assignee
Shenzhen Salubris Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Salubris Pharmaceuticals Co Ltd filed Critical Shenzhen Salubris Pharmaceuticals Co Ltd
Publication of CN115461330A publication Critical patent/CN115461330A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

FXIa抑制剂化合物杂质及其制备方法和用途，包括FXIa抑制剂化合物杂质1、杂质2、杂质4，还公开了杂质的制备方法和用途，提供的FXIa抑制剂化合物相关杂质及其制备方法为FXIa抑制剂化合物原料药及其药物组合物的质量研究提供了基础。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN202280003731.4A 2021-03-18 2022-03-17 FXIa抑制剂化合物杂质及其制备方法和用途 Pending CN115461330A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2021102913349 2021-03-18
CN202110291334 2021-03-18
CN2021114793780 2021-12-06
CN202111479378 2021-12-06
CN202111682702 2021-12-31
CN2021116827029 2021-12-31
PCT/CN2022/081291 WO2022194225A1 (zh) 2021-03-18 2022-03-17 FXIa抑制剂化合物杂质及其制备方法和用途FXIa抑制剂化合物杂质及其制备方法和用途

Publications (1)

Publication Number Publication Date
CN115461330A true CN115461330A (zh) 2022-12-09

Family

ID=83321890

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280003731.4A Pending CN115461330A (zh) 2021-03-18 2022-03-17 FXIa抑制剂化合物杂质及其制备方法和用途

Country Status (3)

Country Link
CN (1) CN115461330A (zh)
TW (1) TW202246219A (zh)
WO (1) WO2022194225A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115536674A (zh) * 2022-11-03 2022-12-30 青岛科技大学 一种哒嗪螺苯并磺内酰胺化合物及其合成方法与用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101341129A (zh) * 2005-12-14 2009-01-07 布里斯托尔-迈尔斯斯奎布公司 作为因子xia抑制剂的芳基丙酰胺，芳基丙烯酰胺，芳基丙炔酰胺，或芳基甲基脲类似物
CN103242198A (zh) * 2013-04-25 2013-08-14 哈药集团制药总厂 一种来曲唑杂质的制备方法
CN107793396A (zh) * 2016-08-31 2018-03-13 江苏恒瑞医药股份有限公司 环氧基取代的氧代吡啶类衍生物、其制备方法及其在医药上的应用
CN108137549A (zh) * 2015-08-05 2018-06-08 百时美施贵宝公司 新颖的取代的甘氨酸衍生的fxia抑制剂
US20190185464A1 (en) * 2016-08-31 2019-06-20 Jiangsu Hengrui Medicine Co., Ltd. Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof
CN112675173A (zh) * 2020-12-25 2021-04-20 华南理工大学 FXIa抑制剂化合物或其盐的医药用途
CN115515938A (zh) * 2020-10-23 2022-12-23 深圳信立泰药业股份有限公司 FXIa抑制剂化合物的盐及其制备方法和医药用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3152667A1 (en) * 2019-09-27 2021-04-01 Shenzhen Salubris Pharmaceuticals Co. Ltd. Fxia inhibitors and preparation method therefor and pharmaceutical use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101341129A (zh) * 2005-12-14 2009-01-07 布里斯托尔-迈尔斯斯奎布公司 作为因子xia抑制剂的芳基丙酰胺，芳基丙烯酰胺，芳基丙炔酰胺，或芳基甲基脲类似物
CN103242198A (zh) * 2013-04-25 2013-08-14 哈药集团制药总厂 一种来曲唑杂质的制备方法
CN108137549A (zh) * 2015-08-05 2018-06-08 百时美施贵宝公司 新颖的取代的甘氨酸衍生的fxia抑制剂
CN107793396A (zh) * 2016-08-31 2018-03-13 江苏恒瑞医药股份有限公司 环氧基取代的氧代吡啶类衍生物、其制备方法及其在医药上的应用
US20190185464A1 (en) * 2016-08-31 2019-06-20 Jiangsu Hengrui Medicine Co., Ltd. Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof
CN115515938A (zh) * 2020-10-23 2022-12-23 深圳信立泰药业股份有限公司 FXIa抑制剂化合物的盐及其制备方法和医药用途
CN112675173A (zh) * 2020-12-25 2021-04-20 华南理工大学 FXIa抑制剂化合物或其盐的医药用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
王维剑，等: "药品杂质控制与评价研究进展", 药学研究, vol. 36, no. 11, pages 1 - 6 *
王菊，等: "新型高选择性URAT1抑制剂HR011303的有关物质研究", 药物分析杂志, vol. 12, no. 04, pages 148 - 152 *

Also Published As

Publication number Publication date
TW202246219A (zh) 2022-12-01
WO2022194225A1 (zh) 2022-09-22

Similar Documents

Publication Publication Date Title
EP3741756B1 (en) Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor
EP3578561A1 (en) Spiro compounds
HUE030685T2 (en) Macrocyclic purines for treating viral infections
CN115461330A (zh) FXIa抑制剂化合物杂质及其制备方法和用途
CN116444529B (zh) 一种氘代氮杂环丁烷类jak抑制剂及其用途
CN107286220B (zh) 1,2,4-三氮唑偶联的二氢杨梅素衍生物及其制备方法和应用
CA2673510C (en) Maleic acid monosalt of antiviral agent and pharmaceutical composition containing the same
CN110437156B (zh) 丹皮酚二氢嘧啶酮类衍生物及其制备方法和应用
CN111393401A (zh) 一种基于罗丹明衍生物检测心肌黄酶的荧光探针分子及制备方法和用途
CN115385859A (zh) 一种可细胞内自组装的蛋白降解剂及其制备方法和应用
CN115515938A (zh) FXIa抑制剂化合物的盐及其制备方法和医药用途
CN115286687A (zh) 一种基于生物正交反应的细胞内自组装降解剂及其制备方法和应用
CN115403561A (zh) 一种基于沙利度胺类似物的细胞内自组装蛋白降解剂及其制备方法和应用
KR102397741B1 (ko) 세고리식 화합물의 결정 형태 및 이의 용도
CN113880855A (zh) 一种9-氟喜树碱衍生物的制备及其在抗肿瘤方面的用途
CN110194741B (zh) 4-苯甲酰哌嗪-3-硝基-1,8-萘酰亚胺衍生物及其制备方法和应用
EP3925960B1 (en) Fgfr inhibitor compound in solid form and preparation method therefor
CN114133390A (zh) 一种去氢骆驼蓬碱衍生物及其制备方法和应用
CN115124464B (zh) 一种喹啉二酮磺酰哌嗪杂合体及其制备方法和应用
CN116496280B (zh) 氘代丙烯酰胺类jak3抑制剂药物及用途
CN108409754A (zh) 依度沙班氧化降解杂质的制备方法及用途
CN115572294B (zh) 一种氘代氮杂吲哚联吡唑类化合物、药物组合物和用途
CN112961081B (zh) 一种联苯甲酰胺脲类化合物及其制备方法和应用
CN115181102B (zh) 含有1h-吡唑并[3,4-d]嘧啶结构的cdk8抑制剂
CN112375112B (zh) 一种苯并咪唑衍生物bi361及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination